Cytek Q4 revenue $62.1M (+8% YoY); net loss $44.1M on $38.1M deferred tax valuation allowance

Cytek Biosciences, Inc.

Full-year 2025 revenue $201.5M (+1% YoY); Q4 set record quarterly revenue.
GAAP gross margin 53% in Q4 vs 59% a year ago; adjusted gross margin 55% vs 61%.
Full-year net loss $66.5M vs $6.0M in 2024, driven by $33.1M non-cash deferred tax valuation allowance and higher expenses.
Adjusted EBITDA for 2025 was $5.0M, down from $22.4M; excluding investment income, was $(3.1)M.
Guides FY2026 revenue of $205-212M, representing 2-5% growth over 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.